OpenURL Connection Search - EBSCO

Connecting you to content on EBSCOhost

Select item for more details and to access through your institution.

Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo.
Published in:
2012
By:
- Ackler S;
- Mitten MJ;
- Chen J;
- Clarin J;
- Foster K;
- Jin S;
- Phillips DC;
- Schlessinger S;
- Wang B;
- Leverson JD;
- Boghaert ER;
- Ackler, S;
- Mitten, M J;
- Chen, J;
- Clarin, J;
- Foster, K;
- Jin, S;
- Phillips, D C;
- Schlessinger, S;
- Wang, B
Publication type:
journal article
Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo.
Published in:
British Journal of Pharmacology, 2012, v. 167, n. 4, p. 881, doi. 10.1111/j.1476-5381.2012.02048.x
By:
- Ackler, S;
- Mitten, MJ;
- Chen, J;
- Clarin, J;
- Foster, K;
- Jin, S;
- Phillips, DC;
- Schlessinger, S;
- Wang, B;
- Leverson, JD;
- Boghaert, ER
Publication type:
Article